2024 ASCO-GU progress in non-clear cell renal cell carcinoma
10.3760/cma.j.cn112330-20240417-00001
- VernacularTitle:2024 ASCO-GU非透明细胞肾细胞癌研究进展
- Author:
Wen KONG
1
;
Zhenhua LIU
;
Jin ZHANG
;
Hao ZENG
Author Information
1. 上海交通大学医学院附属仁济医院泌尿外科，上海 200127
- Keywords:
TKI-IO combination;
Tumor microenvironment;
Fusion partner
- From:
Chinese Journal of Urology
2024;45(4):251-253
- CountryChina
- Language:Chinese
-
Abstract:
One of the remarkable progresses regarding non-clear cell renal cell carcinoma in the 2024 ASCO-GU symposium was the survival update of KEYNOTE-B61 study, in which tyrosine kinase inhibitor plus immunotherapy (TKI-IO) combination maintained satisfactory efficacy and safety. The distinct response to immunotherapy between papillary versus chromophobe renal cell carcinoma was demonstrated closely correlated with tumor microenvironment. The fusion partner of TFE-rearranged renal cell carcinoma directly determined the tumor biological behavior and therapeutic response.
